The world's fastest LCMS/MS tandem mass spectrometer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The world’s fastest LCMS/MS tandem mass spectrometer

Expanded range of ultra-fast, high-sensitivity applications

Shimadzu’s LCMS-8040 combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection.

A five-fold increase in sensitivity (reserpine, S/N ratio) has been achieved in comparison to the LCMS-8030 model by improving ion focusing and minimizing ion losses between multi-pole lenses.

The fastest scan speed of 15,000 u/s and the fastest polarity switching time of 15 msec, already known from the LCMS-8030, expand in combination with the higher sensitivity the potential range of LC/MS/MS applications. The LCMS-8040 achieves multiple reaction monitoring (MRM) transition speeds of up to 555 MRMs per second utilizing UFsweeper II collision cell technology. UFsweeper II features high-speed ion transport technology that maintains sensitivity and suppresses crosstalk, even for high-speed or simultaneous multi-component analyses.

LabSolutions LCMS software offers a variety of data processing features, including a Quantitation Browser which processes multiple analytes, and a Data Browser which allows users to analyze and compare multiple sets of data in the same window.

For more information please visit www.shimadzu.eu.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here